Current Status of Monoclonal antibody therapy for Chronic Lymphocytic Leukemia

ONCOLOGY

Volumn 17, Issue 2, 2003, Pages 253-262

  Nabhan, Chadi ^a   Lurie, Robert H ^d   Dyer, Martin J ^b   Rosen, Steven T ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c North Park University   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANIMAL; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DISEASE FREE SURVIVAL; HUMAN; MORTALITY; PROGNOSIS; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DISEASE-FREE SURVIVAL; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; NEOPLASM STAGING; PROGNOSIS;

EID: 0037628994     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Greenlee RT, Murray T, Bolden S, et al: Cancer statistics, 2000. CA Cancer J Clin 50:7- 33, 2000.
2. Rai KR, Sawitsky A, Cronkite EP, et al: Clinical staging of chronic lymphocytic leukemia. Blood 46:219-234, 1975.
3. Rai KR, Peterson BL, Appelbaum FR, et al: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leuemia. N Engl J Med 343:1750-1757, 2000.
4. Larson S, Divgi C, Sgouros G, et al: Monoclonal antibodies: Basic principles, radioisotope conjugates, in Rosenberg SA (ed): Principles and Practice of the Biologic Therapy of Cancer, pp 396-412. Philadelphia, Lip- pincott Williams & WiIkins, 2000.
5. Dyer M, Osterborg A: The use of therapeutic monoclonal antibodies in chronic lymphocytic leukemia, in Cheson B (ed): Chronic Lymphocytic Leukemias, pp 335-352. New York, Marcel Dekker, 2001.
6. Cartron G, Dacheux L, Salles G, et al: Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgRIIIa gene. Blood 99:754-758, 2002.
7. Weng WK, Levy R: Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non- Hodgkin lymphoma. Blood 98:1352-1357, 2001.
8. Byrd JC, Kitada S, Flinn IW, et al: The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: Evidence of caspase activation and apoptosis induction. Blood 99:1038-1043, 2002.
9. Shan D, Ledbetter JA, Press OW: Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 91:1644-1652, 1998.
10. Reff ME, Carner K, Chambers KS, et al: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435-445, 1994.
11. Anderson KC, Bates MP, Slaughenhoupt BL, et al: Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation. Blood 63:1424-1433, 1984.
12. Tedder TF, Disteche CM, Louie E, et al: The gene that encodes the human CD20 (Bl) differentiation antigen is located on chromosome 11 near the t(l I;14)(ql3;q32) translocation site. J Immunol 142:2555-2559, 1989.
13. 13, Tedder TF, Streuli M, Schlossman SF, et ak'Isoâtion and structure of a cDNA encoding the Bl (CD20) cell-surface antigen of human B lymphocytes. Proc Natl Acad Sci USA 85:208-212, 1988.
14. 14.0'Keefe TL, Williams GT, Davies SL, et al: Mice carrying a CD20 gene disruption. Immunogenetics 48:125-132, 1998.
15. McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four- dose treatment program. J Clin Oncol 16:2825-2833, 1998.
16. Davis TA, White CA, Grillo-Lopez AJ, et al: Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a phase II trial of rituximab. J Clin Oncol 17:1851-1857, 1999.
17. Gutheil J, Finucane D, Rodriguez R, et al: Phase II study of Rituximab (Rituxan) in patients with previously untreated low-grade or follicular non-Hodgkin's lymphoma (abstract 79). Proc Am Soc Clin Oncol 19:22a, 2000.
18. Winkler U, Schulz H, Jensen M, et al: Toxicity and efficacy of the anti-CD20 antibody rituximab (Rituxan) in patients with B- cell chronic lymphocytic leukemia: A phase 1/ II study (abstract 1396). Blood 94:312a, 1999.
19. Huhn D, von Schilling C, Wilhelm M, et al: Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98:1326-1331, 2001.
20. O'Brien SM, Kantarjian H, Thomas DA, et al: Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19:2165-2170, 2001.
21. Byrd JC, Murphy T, Howard RS, et al: Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 19:2153-2164, 2001.
22. Hainsworth J, Litchy S, Burris H, et al: Rituximab as first-line and maintenance therapy for patients with small lymphocytic lymphoma (SLL) and chronic lymphocytic leukemia (CLL) (abstract 1530). J Clin Oncol 20:4261-4267, 2002.
23. Nguyen DT, Amess JA, Doughty H, et al: IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non- Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. Eur J Haematol 62:76-82, 1999.
24. Manshouri T, SafferH, Keating M: Clinical relevance of circulating CD 20 (cCD 20) in patients with chronic lymphocytic leukemia (CLL) (abstract 1595). Blood 96:369a, 2000.
25. Petryk M, Grossbard M: Rituximab therapy of B-cell neoplasms. Clin Lymphoma 1:186-194, 2000.
26. Rai K, Gupta N, Janson D, et al: Ritux- imab/cyclophosphomide/ dexamethasone combination highly effective in autoimmune hemolytic anemia associated with chronic lymphocytic leukemia (abstract 3264). Blood 96:754a, 2000.
27. Gupta N, Patel D, Kavuru S, et al: Re- treatment with a rituximab based therapy is highly effective in autoimmune hemolytic anemia (AIHA) associated with chronic lymphocytic leukemia (CLL) (abstract 1529). Blood 98:363a, 2001.
28. Byrd JC, Waselenko JK, ManeatisXI, et al: Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: Association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 17:791-795, 1999.
29. Yang H, Rosove MH, Figlin RA: Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: High-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Am J He- matol 62:247-250, 1999.
30. Maloney DG: Preclinical and phase I and II trials of rituximab. Semin Oncol 26:74-78, 1999.
31. Dyer MJ, Hale G, Hayhoe FG, et al: Effects of CAMPATH-I antibodies in vivo in patients with lymphoid malignancies: Influence of antibody isotype. Blood 73:1431-1439, 1989.
32. Hale G, Xia MQ, Tighe HP, et al: The CAMPATH-1 antigen (CDw52). Tissue Antigens 35:1181-1227, 1990.
33. Riechmann L, Clark M, Waldmann H, et al: Reshaping human antibodies for therapy. Nature 332:323-327, 1988.
34. Hale G, Dyer MJ, Clark MR, et al: Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1 H. Lancet 2:1394-1399, 1988.
35. Gilleece MH, Dexter TM: Effect of Cam- path-lH antibody on human hematopoietic progenitors in vitro. Blood 82:807-812, 1993.
36. Salisbury JR, Rapson NT, Codd JD, et al: Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas. J Clin Pathol 47:313-317, 1994.
37. Lundin J, Osterborg A, Brittinger G, et al: CAMPATH-1 H monoclonal antibody in therapy for previously treated low-grade non- Hodgkin's lymphomas: A phase II multicenter study. European Study Group of CAMPATH- 1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. J Clin Oncol 16:3257-3263, 1998.
38. Lim SH, Davey G, Marcus R: Differential response in a patient treated with Campath- IH monoclonal antibody for refractory non-Hodgkin lymphoma. Lancet 341:432-433, 1993.
39. Pawson R, Dyer MJ, Barge R, et al: Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol 15:2667-2672, 1997.
40. Dearden CE, Matutes E, Cazin B, et al: High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 98:1721-1726, 2001.
41. Osterborg A, Dyer MJ, Bunjes D, et al: Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 15:1567-1574, 1997.
42. Keating M, Byrd J, Rai K, et al: Multi- center study of CAMPATH-1H in patients with chronic lymphocytic leukemia refractory to flu- darabine. Blood 99:3554-3561, 2002.
43. Kennedy B, Rawstron A, Evans P, et al: Campath-IH therapy in 29 patients with refractory CLL: True complete remission in an attainable goal (abstract 2683). Blood 94:603a, 1999.
44. Rai K, Coutre S, Rizzieri D, et al: Efficacy and safety of almetuzumab (campath-1H) in refractory B-CLL patients treated on a compassionate basis (abstract 1538). Blood 98:365a, 2001.
45. Osterborg A, Fassas AS, Anagnostopoulos A, et al: Humanized CD52 monoclonal antibody Campath-IH as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol 93:151-153, 1996.
46. Bowen AL, Zomas A, Emmett E, et al: Subcutaneous CAMPATH-IH in fludarabine- resistant/relapsed chronic lymphocytic and B- prolymphocytic leukaemia. Br J Haematol 96:617-619, 1997.
47. Tang SC, Hewitt K, Reis MD, et al: Immunosuppressive toxicity of CAMPATH IH monoclonal antibody in the treatment of patients with recurrent low grade lymphoma. Leak Lymphoma 24:93-101, 1996.
48. Thai C, Nguyen D, Dugan K, et al: Incidence of cytomegalovirus (CMV) viremia during campath-1H therapy for relapsed/refractory chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL) (abstract 1540). Blood 98:366a, 2001.
49. Johnson S, Smith AG, Loffler H, et al: Multicentre prospective randomised trial of flu- darabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 347:1432-1438, 1996.
50. Byrd J, Peterson B, Park K, et al: Concurrent rituximab and fludarabine has a higher complete response rate than sequential treatment in untreated chronic lymphocytic leukemia (CLL) patients: Results from CALGB 9712. Blood 101:6-14, 2003.
51. Schulz H, Klein S, Rehwald U, et al: Phase II study of rituximab in combination with fludarabine in patients with chronic lymphocytic leukemia (CLL) (abstract 1534). Blood 98:364a, 2001.
52. Yamauchi T, Nowak BJ, Keating MJ, et al: DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxy- cyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 7:3580-3589, 2001.
53. O'Brien SM, Kantarjian HM, Cortes J, et al: Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 19:1414- 1420, 2001.
54. Garcia-Manero G, O'Brien S, Cortes J, et al: Update of results of fludarabine, cyclophosphamide, and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL) (abstract 2650). Blood 98:633a, 2001.
55. Wierda W, O'Brien S, Albitar M, et al: Combined fludarabine, cyclophosphamide, and rituximab achieves a high complete remission rate as initial treatment for chronic lymphocytic leukemia (abstract 3210). Blood 2001; 98:771a, 2001.
56. Drapkin R: Pentostatin and rituximab in the treatment of patients with B-cell malignancies. Oncology 14:25-29, 2000.
57. Kennedy B, Rawstron A, Carter C, et al: CAMPATH-IH with fludarabine: A novel, highly active combination in refractory CLL (abstract 703). Blood 96:289b, 2000.
58. Kennedy B, Rawstron A, Carter C, et al: Campath-IH and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 99:2245-2247, 2002.
59. Nabhan C, Rosen ST: Conceptual aspects of combining rituximab and Campath- IH in the treatment of chronic lymphocytic leukemia. Semln Oncol 29:75-80, 2002.
60. Nabhan C, Tallman M, Riley M, et al: Phase I study of rituximab and CAMPATH-IH in patients with relapsed or refractory chronic lymphocytic leukemia (abstract 1536). Blood 98:365a, 2001.
61. Faderl S, Thomas D, O'Brien S, et al: An exploratory study of the combination of monoclonal antibodies CAMPATH-1H and rituximab in the treatment of CD 52 and CD 20 positive chronic lymphoid disorders (abstract 1537). Blood 98:365a, 2001.
62. Leonard J, Coleman M, Matthews J, et al: Combination monoclonal antibody therapy for lymphoma treatment with epratuzumab (anti-CD 22) and rituximab (anti-CD 20) is well tolerated (abstract 3506). Blood 98:844a, 2001.
63. Link B, Kahl B, Czuczman M, et al: A phase II study of Remitogen (HulDIO), a humanized monoclonal antibody in patients with relapsed or refractory follicular, small lymphocytic, or marginal zone/MALT B-cell lymphoma (abstract 2540). Blood 98:606a, 2001.
64. Thomas D, O'Brien S, Giles F: Single agent rituxan in early stage chronic lymphocytic leukemia (CLL) (abstract 1533). Blood 98:364a, 2001.